Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion

2003 ◽  
Vol 48 (6) ◽  
pp. 1504-1512 ◽  
Author(s):  
Rainer H. Straub ◽  
Georg Pongratz ◽  
Jürgen Schölmerich ◽  
Frieder Kees ◽  
Thomas F. Schaible ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Pituitary Gland ◽  
Tumor Necrosis ◽  
Antibody Therapy ◽  
Adrenal Androgen ◽  
Androgen Secretion ◽  
Necrosis Factor

Long-term Survival of Subcutaneous Anti-tumor Necrosis Factor Biological Drugs Administered Between 2008 and 2012 in a Cohort of Rheumatoid Arthritis Patients

2019 ◽  
Vol 15 (1) ◽  
pp. 54-57
Author(s):  
Noelia Alvarez Rivas ◽  
Tomas R. Vazquez Rodriguez ◽  
Jose A. Miranda Filloy ◽  
Carlos Garcia-Porrua ◽  
Amalia Sanchez-Andrade Fernández
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Biological Drugs ◽  
Term Survival ◽  
Long Term Survival ◽  
Necrosis Factor

scholarly journals Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?

2002 ◽  
Vol 46 (7) ◽  
pp. 1971-1972 ◽  
Author(s):  
Philip G. Conaghan ◽  
Mark A. Quinn ◽  
Philip O'Connor ◽  
Richard J. Wakefield ◽  
Zunaid Karim ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
High Dose ◽  
Very High ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document